```html

Chlamydia – Comprehensive Medical Guide

Overview

Chlamydia is a sexually transmitted infection (STI) caused by the bacterium Chlamydia trachomatis. It is the most commonly reported bacterial STI in the United States and many other countries. In 2022, the CDC documented over 1.8 million cases, representing a 6 % increase from the previous year. Although anyone who is sexually active can acquire chlamydia, the highest prevalence is seen among sexually‑active adolescents and young adults aged 15–24, with women generally testing positive at higher rates than men.

Chlamydia can infect the cervix, urethra, rectum, throat, and eyes (through autoinoculation). Most infections are asymptomatic—up to 70 % of women and 50 % of men show no signs—making routine screening essential for sexually active individuals.

Symptoms

Symptoms vary by gender, site of infection, and whether the infection is acute or has become chronic.

Women

• Abnormal vaginal discharge: watery, yellow‑white, often with a mild odor.
• Painful urination (dysuria): burning sensation during or after urination.
• Lower abdominal or pelvic pain: may be intermittent or constant.
• Bleeding between periods or after intercourse: spotting or heavier flow.
• Rectal pain, bleeding, or discharge: occurs with receptive anal intercourse.
• Throat soreness: if infected through oral sex, though often unnoticed.

Men

• Painful urination (dysuria): burning or stinging sensation.
• Pus‑like penile discharge: white, yellow, or clear.
• Testicular pain or swelling: epididymitis in up to 10 % of cases.
• Rectal symptoms: pain, discharge, or bleeding after receptive anal sex.
• Throat soreness: similar to women, often silent.

Other Sites

• Conjunctivitis (eye infection): redness, tearing, and discharge—rare and usually from hand‑to‑eye contact.
• Perinatal infection: newborns can acquire chlamydia during birth, leading to conjunctivitis or pneumonia.

Causes and Risk Factors

Cause: Chlamydia is spread through sexual contact with an infected partner—vaginal, anal, or oral intercourse. The bacterium can survive on mucosal surfaces for several hours, allowing transmission even without ejaculation.

Risk factors include:

• Having unprotected sex (condom or dental dam not used).
• Multiple sexual partners or a partner with other STIs.
• History of prior chlamydia or other STIs.
• Age < 25 years (behavioral factors and cervical ectopy in women increase susceptibility).
• Inconsistent or incorrect condom use.
• Substance use that impairs judgment (alcohol, drugs).
• Poor access to sexual health services or screening programs.

Diagnosis

Because chlamydia is often silent, laboratory testing is the cornerstone of diagnosis.

Specimen collection

• Women: First‑catch urine (FCU) or self‑collected vaginal swabs (most sensitive). Cervical swabs collected by a clinician are also acceptable.
• Men: FCU or urethral swab if discharge is present.
• Rectal and throat sites: Swabs specific to the site if exposure is likely.

Tests used

• Nucleic Acid Amplification Test (NAAT): Gold‑standard, >95 % sensitivity, can be performed on urine or swabs. Recommended by CDC, WHO, and NICE.
• Direct fluorescent antibody (DFA) and culture: Less common, used mainly for research or when NAAT is unavailable.
• Rapid point‑of‑care tests: Emerging technologies provide results in <30 minutes, but sensitivity is still lower than NAAT.

Pregnant women are screened at the first prenatal visit, and repeat testing is advised at 28–32 weeks if risk persists.

Treatment Options

Chlamydia responds well to short courses of antibiotics. Prompt treatment reduces transmission and prevents complications.

First‑line regimens (CDC 2021 guidelines)

• Doxycycline 100 mg orally twice daily for 7 days – most effective for urogenital, rectal, and pharyngeal infections.
• Azelithromycin 1 g orally in a single dose – alternative for patients who cannot take doxycycline (e.g., pregnancy, doxycycline allergy). Note: Recent data suggest slightly lower efficacy for rectal infections.

Special populations

• Pregnant or breastfeeding women: Azithromycin 1 g single dose or amoxicillin 500 mg three times daily for 7 days.
• Allergic to both doxycycline and azithromycin: Erythromycin 500 mg four times daily for 7 days.

Partner management

All sexual partners within the previous 60 days should receive empirical treatment (“expedited partner therapy” when allowed by law). Retesting is recommended three months after treatment to detect reinfection.

Lifestyle and supportive care

• Avoid sexual activity until both patient and partners have completed therapy (usually 7 days).
• Continue condom use consistently.
• Hydration and over‑the‑counter pain relievers (ibuprofen or acetaminophen) for discomfort.

Living with Sexually Transmitted Infection (Chlamydia)

Managing chlamydia is straightforward once diagnosed, but the emotional and practical aspects can be challenging.

• Adherence: Finish the full antibiotic course, even if symptoms resolve.
• Follow‑up testing: Retest 3 months after treatment (or sooner if re‑exposed) to confirm cure.
• Disclosure: Communicating with current and past partners is essential to stop spread.
• Emotional health: Feelings of shame or anxiety are common; consider counseling or support groups.
• Routine screening: Annual chlamydia screening for sexually active women <25 years and men who have sex with men (MSM) is recommended.
• Vaccination: No vaccine exists for chlamydia, but staying up‑to‑date on HPV and hepatitis B vaccines reduces overall STI risk.

Prevention

Preventing chlamydia involves a combination of behavioral, barrier, and health‑system strategies.

• Consistent condom use: Latex or polyurethane condoms reduce transmission by ~50 % when used correctly.
• Dental dams for oral‑anal contact: Particularly important for MSM and those engaging in oral‑anal sex.
• Regular screening: At least yearly for sexually active women <25 years, pregnant women, and high‑risk men.
• Limiting number of sexual partners: Fewer partners lower exposure risk.
• Mutual monogamy: Both partners tested and confirmed negative before ending condom use.
• Vaccination and prophylaxis for other STIs: Reduces co‑infection that can increase susceptibility.
• Education: Comprehensive sexual health education improves condom use and testing uptake.

Complications

If left untreated, chlamydia can cause serious short‑ and long‑term health problems.

In Women

• Pelvic Inflammatory Disease (PID): Up to 10‑15 % of untreated infections progress to PID, leading to chronic pelvic pain and infertility.
• Ectopic pregnancy: Damaged fallopian tubes increase risk; ectopic pregnancy accounts for 2‑3 % of all pregnancies in women with prior PID.
• Infertility: Tubal scarring reduces the chance of natural conception.
• Increased HIV susceptibility: Inflammation facilitates viral entry.

In Men

• Epididymitis: Painful swelling of the epididymis; may affect fertility if chronic.
• Prostatitis and urethritis: Persistent discomfort and urinary symptoms.
• Reiter’s syndrome (reactive arthritis): Joint pain, conjunctivitis, and urethritis occurring weeks after infection.

In Both Sexes

• Increased risk of acquiring or transmitting HIV, syphilis, and gonorrhea.
• Reactive arthritis (Reiter’s syndrome).
• Psychosocial impacts: stigma, anxiety, and relationship strain.

When to Seek Emergency Care

Key Take‑aways

• Chlamydia is the most common bacterial STI; many infections are asymptomatic.
• Routine screening for sexually active individuals under 25 and high‑risk groups is essential.
• NAAT on urine or swab samples provides accurate diagnosis.
• Seven days of doxycycline is the preferred treatment; azithromycin is an alternative when needed.
• Prompt treatment and partner therapy prevent PID, infertility, and onward transmission.
• Consistent condom use, limiting partners, and regular testing are the most effective prevention measures.

For personalized advice, schedule an appointment with your primary care provider or a local sexual health clinic. Early detection and treatment make chlamydia a fully curable infection.

```